Articles Tagged With: Pharmacology
-
Brensocatib Tablets (Brinsupri)
The U.S. Food and Drug Administration has approved brensocatib, the first dipeptidyl peptidase-1 inhibitor and the first drug approved for non-cystic fibrosis bronchiectasis.
-
Sunvozertinib (Zegfrovy) Tablets
The U.S. Food and Drug Administration (FDA) has granted an accelerated approval to sunvozertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (EGFR exon20ins). The FDA also approved a companion diagnostic device, Oncomine Dx Express Test to help detect exon20ins mutations.
-
Fidaxomicin Is More Clinically Effective than Vancomycin for C. difficile Infection
There is a lack of real-world data on using fidaxomicin for Clostridioides difficile infection (CDI). A retrospective, single-center study found that treatment of CDI with fidaxomicin leads to reduced clinical failure compared to oral vancomycin.
-
Lenacapavir Injection and Tablets (Yeztugo)
The U.S. Food and Drug Administration has approved lenacapavir, a potent, first-in-class, capsid inhibitor, for reducing the risk of sexually acquired human immunodeficiency virus type 1.
-
Avutometinib Capsules and Defactinib Tablets (Avmapki Fakzynja CO-PACK)
The U.S. Food and Drug Administration has granted accelerated approval for a combination of two kinase inhibitors, avutometinib and defactinib, for the treatment of KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, including a platinum-based regimen.
-
Telisotuzumab Vedotin-tlly (Emrelis)
The U.S. Food and Drug Administration has granted accelerated approval of telisotuzumab vedotin-tilly, a first-in-class c-mesenchymal-epithelial transition factor-directed antibody and a microtubule inhibitor conjugate for the treatment of locally advanced or metastatic, non-squamous non-small cell lung cancer.
-
New Injectable Cholesterol-Lowering Drug Trial
A comparison of inclisiran therapy to placebo and ezetimibe therapy over six months in primary prevention patients at low risk of atherosclerotic cardiovascular disease and not taking lipid-lowering therapy has shown that inclisiran subcutaneously every six months reduces low-density lipoprotein cholesterol more than ezetimibe and is comparable to the reported results of high-dose statins taken daily.
-
Nipocalimab-aahu Injection (Imaavy)
The U.S. Food and Drug Administration has approved a neonatal Fc-receptor (FcRn) blocker for the treatment of generalized myasthenia gravis. Nipocalimab-aahu is a recombinant human immunoglobulin G1 lambda monoclonal antibody directed at FcRn with high affinity and selectivity.
-
Gepotidacin Tablets (Blujepa)
The U.S. Food and Drug Administration has approved gepotidacin, a first-in-class antibacterial medication for the treatment of uncomplicated urinary tract infections.
-
Aztreonam and Avibactam for Injection (Emblaveo)
The U.S. Food and Drug Administration has approved a new combination antibiotic for the treatment of complicated intra-abdominal infections where there are limited or no alternative options.